Bio-Connect

PAK6 antibody

GTX78127
GeneTex
ApplicationsImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityCanine, Equine, Human, Monkey
TargetPAK6
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    PAK6 antibody
  • Delivery Days Customer
    9
  • Application Supplier Note
    IHC-P: 3.5 microg/ml. IHC-P: 3.5 microg/ml. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Applications
    ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Concentration
    1 mg/ml
  • Conjugate
    Unconjugated
  • Gene ID56924
  • Target name
    PAK6
  • Target description
    p21 (RAC1) activated kinase 6
  • Target synonyms
    p21 protein (Cdc42/Rac)-activated kinase 6; p21(CDKN1A)-activated kinase 6; PAK5; serine/threonine-protein kinase PAK 6
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDQ9NQU5
  • Protein Name
    Serine/threonine-protein kinase PAK 6
  • Scientific Description
    This gene encodes a member of a family of p21-stimulated serine/threonine protein kinases, which contain an amino-terminal Cdc42/Rac interactive binding (CRIB) domain and a carboxyl-terminal kinase domain. These kinases function in a number of cellular processes, including cytoskeleton rearrangement, apoptosis, and the mitogen-activated protein (MAP) kinase signaling pathway. The protein encoded by this gene interacts with androgen receptor (AR) and translocates to the nucleus, where it is involved in transcriptional regulation. Changes in expression of this gene have been linked to prostate cancer. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2015]
  • Reactivity
    Canine, Equine, Human, Monkey
  • Storage Instruction
    -20°C or -80°C,2°C to 8°C
  • UNSPSC
    12352203

References

  • Predictive value of PAK6 and PSMB4 expression in patients with localized prostate cancer treated with dose-escalation radiation therapy and androgen deprivation therapy. Zapatero A et al., 2014 Nov, Urol Oncol
    Read more